Literature DB >> 1746291

Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production.

M Maes1, E Bosmans, E Suy, C Vandervorst, C DeJonckheere, J Raus.   

Abstract

In an attempt to delineate the pathophysiology underpinning the previously reported blunted lymphocyte responses to mitogenic stimulation in depressed patients, we measured the following immune variables in 28 depressives and 10 healthy controls: pre- and postdexamethasone (1 mg orally) lymphocyte responses to various mitogens, such as phytohaemagglutinin (PHA), and the PHA-induced accumulation of interleukin-1 beta (Il-1 beta) and soluble interleukin-2-receptors (sIl-2Rs) in culture supernatants. In the predexamethasone state, we found significantly more mitogen-stimulated blastogenesis in minor depressives vs healthy controls and major depressives. In depressed subjects there was a significant inverse relationship between the severity of illness and the mitogen-induced lymphocyte responses. Melancholics exhibited significantly more Il-1 beta accumulation in PHA culture supernatant than healthy controls. In healthy controls--but not in depressed patients--the sIl-2R accumulation perfectly reflects the magnitude of the PHA-induced lymphocyte stimulation. Dexamethasone administration significantly suppressed the lectin-induced blastogenesis and the Il-1 beta production rate in normal volunteers, whereas depressives exhibited dexamethasone nonsuppression in those factors. Healthy controls exhibited significantly less postdexamethasone blast transformation, Il-1 beta and sIl-2Rs accumulation in culture supernatant than the depressed patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1746291     DOI: 10.1111/j.1600-0447.1991.tb03163.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  48 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression.

Authors:  Michael Maes
Journal:  Metab Brain Dis       Date:  2012-07-07       Impact factor: 3.584

Review 3.  Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.

Authors:  Michael Maes; Gabriel Nowak; Javier R Caso; Juan Carlos Leza; Cai Song; Marta Kubera; Hans Klein; Piotr Galecki; Cristiano Noto; Enrico Glaab; Rudi Balling; Michael Berk
Journal:  Mol Neurobiol       Date:  2015-05-02       Impact factor: 5.590

Review 4.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

5.  Cross-species evidence for the role of interleukin-33 in depression risk.

Authors:  Anastacia Y Kudinova; Terrence Deak; Cara M Hueston; John E McGeary; Valerie S Knopik; Rohan H C Palmer; Brandon E Gibb
Journal:  J Abnorm Psychol       Date:  2016-04-07

Review 6.  Nutrition and depression: implications for improving mental health among childbearing-aged women.

Authors:  Lisa M Bodnar; Katherine L Wisner
Journal:  Biol Psychiatry       Date:  2005-07-25       Impact factor: 13.382

7.  Distinct inflammatory response patterns are evident among men and women with higher depressive symptoms.

Authors:  Marzieh Majd; Jennifer E Graham-Engeland; Joshua M Smyth; Martin J Sliwinski; Richard B Lipton; Mindy J Katz; Christopher G Engeland
Journal:  Physiol Behav       Date:  2017-11-10

Review 8.  Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression.

Authors:  Renaud Massart; Raymond Mongeau; Laurence Lanfumey
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

9.  Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder.

Authors:  Marcin Siwek; Magdalena Sowa-Kućma; Krzysztof Styczeń; Paulina Misztak; Rafał J Nowak; Bernadeta Szewczyk; Dominika Dudek; Janusz K Rybakowski; Gabriel Nowak; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-09-23       Impact factor: 5.590

10.  Antidepressant-like effect of celecoxib piroxicam in rat models of depression.

Authors:  Ronise M Santiago; Janaína Barbiero; Bruno J Martynhak; Suelen L Boschen; Luisa M da Silva; Maria F P Werner; Claudio Da Cunha; Roberto Andreatini; Marcelo M S Lima; Maria A B F Vital
Journal:  J Neural Transm (Vienna)       Date:  2014-01-24       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.